Intracameral bevacizumab and mitomycin C Trabeculectomy for eyes with neovascular glaucoma: a case series
The purpose of this study was to describe the surgical outcomes and safety of intracameral bevacizumab during trabeculectomy in eyes with neovascular glaucoma. Pilot study included four eyes (four patients) with refractory neovascular glaucoma submitted to fornix-based trabeculectomy with adjunctive...
Gespeichert in:
| Veröffentlicht in: | Journal of ocular biology, diseases, and informatics diseases, and informatics, 2009-03, Vol.2 (1), p.40-46 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 46 |
|---|---|
| container_issue | 1 |
| container_start_page | 40 |
| container_title | Journal of ocular biology, diseases, and informatics |
| container_volume | 2 |
| creator | de Moraes, Carlos Gustavo Vasconcelos Facio, Antonio Carlos Costa, José Humberto Malta, Roberto Freire Santiago |
| description | The purpose of this study was to describe the surgical outcomes and safety of intracameral bevacizumab during trabeculectomy in eyes with neovascular glaucoma. Pilot study included four eyes (four patients) with refractory neovascular glaucoma submitted to fornix-based trabeculectomy with adjunctive use of bevacizumab in the anterior chamber during the procedure. Patients were previously treated with panretinal photocoagulation as standard therapy. Variables evaluated were intraocular pressure, bleb appearance, iris neovascularization, intraoperative/postoperative complications, and visual outcomes. No intraoperative complication was observed. The mean follow-up period was 12.75 (range, 12–15 months). All eyes showed significant intraocular pressure control postoperatively. Iris neovascularization reduced significantly within 1 month after surgery. Mild anterior chamber inflammation was observed during follow-up in all eyes. No significant postoperative complication was observed, and no patient presented visual acuity deterioration. Intracameral bevacizumab may be used as an adjunctive therapy during trabeculectomy in eyes with neovascular glaucoma. |
| doi_str_mv | 10.1007/s12177-009-9020-z |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2802500</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>734235340</sourcerecordid><originalsourceid>FETCH-LOGICAL-c308z-bbee2579480d7a74c55239446edfcc5c33001c401fce702db073ffb7c35fa5a73</originalsourceid><addsrcrecordid>eNp9UUtvEzEQthCIlsIP4IJ847QwfsVZDkgo4lGpEpdytmZnZ1NX-yh2NlXy6_EqpSoXTmPN9xjPfEK8VfBBAfiPWWnlfQVQVzVoqI7PxLmqzapaW-ueP3mfiVc53wKsjDPwUpzpotYr689FvBx3CQkHTtjLhvdI8TgP2EgcWznE3TQcKI5yI68TNkxzz7T0ZDclyQfO8j7ubuTI0x5zQTHJbY8zTQN-kigJM8vMKXJ-LV502Gd-81AvxK9vX683P6qrn98vN1-uKjKwPlZNw6ydr-0aWo_eknPa1NauuO2IHBkDoMiC6og96LYBb7qu8WRchw69uRCfT753czNwS7ws2Ie7FAdMhzBhDP8iY7wJ22kf9Bq0AygG7x8M0vR75rwLQ8zEfY9lyzkHb6wud7QLU52YlKacE3ePUxSEJaFwSiiUhMKSUDgWzbun33tU_I2kEPSJkAs0bjmF22lOYznZf1z_ALs5n6M</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>734235340</pqid></control><display><type>article</type><title>Intracameral bevacizumab and mitomycin C Trabeculectomy for eyes with neovascular glaucoma: a case series</title><source>PubMed Central</source><source>EZB Electronic Journals Library</source><creator>de Moraes, Carlos Gustavo Vasconcelos ; Facio, Antonio Carlos ; Costa, José Humberto ; Malta, Roberto Freire Santiago</creator><creatorcontrib>de Moraes, Carlos Gustavo Vasconcelos ; Facio, Antonio Carlos ; Costa, José Humberto ; Malta, Roberto Freire Santiago</creatorcontrib><description>The purpose of this study was to describe the surgical outcomes and safety of intracameral bevacizumab during trabeculectomy in eyes with neovascular glaucoma. Pilot study included four eyes (four patients) with refractory neovascular glaucoma submitted to fornix-based trabeculectomy with adjunctive use of bevacizumab in the anterior chamber during the procedure. Patients were previously treated with panretinal photocoagulation as standard therapy. Variables evaluated were intraocular pressure, bleb appearance, iris neovascularization, intraoperative/postoperative complications, and visual outcomes. No intraoperative complication was observed. The mean follow-up period was 12.75 (range, 12–15 months). All eyes showed significant intraocular pressure control postoperatively. Iris neovascularization reduced significantly within 1 month after surgery. Mild anterior chamber inflammation was observed during follow-up in all eyes. No significant postoperative complication was observed, and no patient presented visual acuity deterioration. Intracameral bevacizumab may be used as an adjunctive therapy during trabeculectomy in eyes with neovascular glaucoma.</description><identifier>ISSN: 1936-8445</identifier><identifier>ISSN: 1936-8437</identifier><identifier>EISSN: 1936-8445</identifier><identifier>DOI: 10.1007/s12177-009-9020-z</identifier><identifier>PMID: 20072647</identifier><language>eng</language><publisher>New York: Humana Press Inc</publisher><subject>Health Informatics ; Medicinal Chemistry ; Medicine ; Medicine & Public Health ; Neurobiology ; Neurochemistry ; Neurology ; Ophthalmology ; Technical Perspectives ; Technical s</subject><ispartof>Journal of ocular biology, diseases, and informatics, 2009-03, Vol.2 (1), p.40-46</ispartof><rights>The Author(s) 2009</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c308z-bbee2579480d7a74c55239446edfcc5c33001c401fce702db073ffb7c35fa5a73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2802500/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2802500/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20072647$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>de Moraes, Carlos Gustavo Vasconcelos</creatorcontrib><creatorcontrib>Facio, Antonio Carlos</creatorcontrib><creatorcontrib>Costa, José Humberto</creatorcontrib><creatorcontrib>Malta, Roberto Freire Santiago</creatorcontrib><title>Intracameral bevacizumab and mitomycin C Trabeculectomy for eyes with neovascular glaucoma: a case series</title><title>Journal of ocular biology, diseases, and informatics</title><addtitle>j ocul biol dis inform</addtitle><addtitle>J Ocul Biol Dis Infor</addtitle><description>The purpose of this study was to describe the surgical outcomes and safety of intracameral bevacizumab during trabeculectomy in eyes with neovascular glaucoma. Pilot study included four eyes (four patients) with refractory neovascular glaucoma submitted to fornix-based trabeculectomy with adjunctive use of bevacizumab in the anterior chamber during the procedure. Patients were previously treated with panretinal photocoagulation as standard therapy. Variables evaluated were intraocular pressure, bleb appearance, iris neovascularization, intraoperative/postoperative complications, and visual outcomes. No intraoperative complication was observed. The mean follow-up period was 12.75 (range, 12–15 months). All eyes showed significant intraocular pressure control postoperatively. Iris neovascularization reduced significantly within 1 month after surgery. Mild anterior chamber inflammation was observed during follow-up in all eyes. No significant postoperative complication was observed, and no patient presented visual acuity deterioration. Intracameral bevacizumab may be used as an adjunctive therapy during trabeculectomy in eyes with neovascular glaucoma.</description><subject>Health Informatics</subject><subject>Medicinal Chemistry</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neurobiology</subject><subject>Neurochemistry</subject><subject>Neurology</subject><subject>Ophthalmology</subject><subject>Technical Perspectives</subject><subject>Technical s</subject><issn>1936-8445</issn><issn>1936-8437</issn><issn>1936-8445</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><recordid>eNp9UUtvEzEQthCIlsIP4IJ847QwfsVZDkgo4lGpEpdytmZnZ1NX-yh2NlXy6_EqpSoXTmPN9xjPfEK8VfBBAfiPWWnlfQVQVzVoqI7PxLmqzapaW-ueP3mfiVc53wKsjDPwUpzpotYr689FvBx3CQkHTtjLhvdI8TgP2EgcWznE3TQcKI5yI68TNkxzz7T0ZDclyQfO8j7ubuTI0x5zQTHJbY8zTQN-kigJM8vMKXJ-LV502Gd-81AvxK9vX683P6qrn98vN1-uKjKwPlZNw6ydr-0aWo_eknPa1NauuO2IHBkDoMiC6og96LYBb7qu8WRchw69uRCfT753czNwS7ws2Ie7FAdMhzBhDP8iY7wJ22kf9Bq0AygG7x8M0vR75rwLQ8zEfY9lyzkHb6wud7QLU52YlKacE3ePUxSEJaFwSiiUhMKSUDgWzbun33tU_I2kEPSJkAs0bjmF22lOYznZf1z_ALs5n6M</recordid><startdate>20090331</startdate><enddate>20090331</enddate><creator>de Moraes, Carlos Gustavo Vasconcelos</creator><creator>Facio, Antonio Carlos</creator><creator>Costa, José Humberto</creator><creator>Malta, Roberto Freire Santiago</creator><general>Humana Press Inc</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20090331</creationdate><title>Intracameral bevacizumab and mitomycin C Trabeculectomy for eyes with neovascular glaucoma: a case series</title><author>de Moraes, Carlos Gustavo Vasconcelos ; Facio, Antonio Carlos ; Costa, José Humberto ; Malta, Roberto Freire Santiago</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c308z-bbee2579480d7a74c55239446edfcc5c33001c401fce702db073ffb7c35fa5a73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Health Informatics</topic><topic>Medicinal Chemistry</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neurobiology</topic><topic>Neurochemistry</topic><topic>Neurology</topic><topic>Ophthalmology</topic><topic>Technical Perspectives</topic><topic>Technical s</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>de Moraes, Carlos Gustavo Vasconcelos</creatorcontrib><creatorcontrib>Facio, Antonio Carlos</creatorcontrib><creatorcontrib>Costa, José Humberto</creatorcontrib><creatorcontrib>Malta, Roberto Freire Santiago</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of ocular biology, diseases, and informatics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>de Moraes, Carlos Gustavo Vasconcelos</au><au>Facio, Antonio Carlos</au><au>Costa, José Humberto</au><au>Malta, Roberto Freire Santiago</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intracameral bevacizumab and mitomycin C Trabeculectomy for eyes with neovascular glaucoma: a case series</atitle><jtitle>Journal of ocular biology, diseases, and informatics</jtitle><stitle>j ocul biol dis inform</stitle><addtitle>J Ocul Biol Dis Infor</addtitle><date>2009-03-31</date><risdate>2009</risdate><volume>2</volume><issue>1</issue><spage>40</spage><epage>46</epage><pages>40-46</pages><issn>1936-8445</issn><issn>1936-8437</issn><eissn>1936-8445</eissn><abstract>The purpose of this study was to describe the surgical outcomes and safety of intracameral bevacizumab during trabeculectomy in eyes with neovascular glaucoma. Pilot study included four eyes (four patients) with refractory neovascular glaucoma submitted to fornix-based trabeculectomy with adjunctive use of bevacizumab in the anterior chamber during the procedure. Patients were previously treated with panretinal photocoagulation as standard therapy. Variables evaluated were intraocular pressure, bleb appearance, iris neovascularization, intraoperative/postoperative complications, and visual outcomes. No intraoperative complication was observed. The mean follow-up period was 12.75 (range, 12–15 months). All eyes showed significant intraocular pressure control postoperatively. Iris neovascularization reduced significantly within 1 month after surgery. Mild anterior chamber inflammation was observed during follow-up in all eyes. No significant postoperative complication was observed, and no patient presented visual acuity deterioration. Intracameral bevacizumab may be used as an adjunctive therapy during trabeculectomy in eyes with neovascular glaucoma.</abstract><cop>New York</cop><pub>Humana Press Inc</pub><pmid>20072647</pmid><doi>10.1007/s12177-009-9020-z</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1936-8445 |
| ispartof | Journal of ocular biology, diseases, and informatics, 2009-03, Vol.2 (1), p.40-46 |
| issn | 1936-8445 1936-8437 1936-8445 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2802500 |
| source | PubMed Central; EZB Electronic Journals Library |
| subjects | Health Informatics Medicinal Chemistry Medicine Medicine & Public Health Neurobiology Neurochemistry Neurology Ophthalmology Technical Perspectives Technical s |
| title | Intracameral bevacizumab and mitomycin C Trabeculectomy for eyes with neovascular glaucoma: a case series |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T16%3A35%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intracameral%20bevacizumab%20and%20mitomycin%20C%20Trabeculectomy%20for%20eyes%20with%20neovascular%20glaucoma:%20a%20case%20series&rft.jtitle=Journal%20of%20ocular%20biology,%20diseases,%20and%20informatics&rft.au=de%20Moraes,%20Carlos%20Gustavo%20Vasconcelos&rft.date=2009-03-31&rft.volume=2&rft.issue=1&rft.spage=40&rft.epage=46&rft.pages=40-46&rft.issn=1936-8445&rft.eissn=1936-8445&rft_id=info:doi/10.1007/s12177-009-9020-z&rft_dat=%3Cproquest_pubme%3E734235340%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=734235340&rft_id=info:pmid/20072647&rfr_iscdi=true |